Monoclonal Antibodies Improve Migraine Sensory Processing

Research Summary

A study published in Biomedicines explores the effects of monoclonal antibodies targeting the CGRP pathway on sensory processing and cortical network efficiency in migraine patients. Over three months, 22 patients with episodic migraines received this treatment, resulting in notable changes in visual evoked potentials (VEP), which showed improvement from a lack of habituation to habituation, aligning with healthy control levels. Although somatosensory evoked potentials (SSEP) remained unchanged, exploratory qEEG data suggested improved cortical network efficiency, comparable to controls by the study's end. While these findings suggest adaptive changes, they should not be overinterpreted as definitive disease modification evidence.

Study Details

📄 Title: Three-Month Treatment with Monoclonal Antibodies Targeting the CGRP Pathway Is Associated with Multi-Domain Changes in Sensory Processing and Cortical Network Efficiency in Migraine: Results from a Prospective Case-Control Study.

👥 Research Team: Klehr L et al.

📚 Published In: Biomedicines

📅 Publication Date: 2026 Apr 27

⚕️ Medical Disclaimer: This summary is generated automatically from recent migraine research. Always consult with healthcare professionals for medical advice.